文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

不同时机启动连续性血液净化治疗重症急性胰腺炎的临床效果研究

[Study on the clinical effect of initiating continuous blood purification at different times for severe acute pancreatitis].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2024-01-01
一句话结论回顾性队列显示,诊断SAP后24小时内启动CBP可降低腹腔间隔室综合征发生率并缩短ICU治疗时间,24-48小时启动则更快降低WBC和病情评分、减少胰腺脓肿。

该回顾性队列纳入2020年1月至2023年12月在湖南省人民医院接受CBP治疗的130例SAP患者,按诊断至首次CBP时间分为早期启动组(<24小时,90例)和晚期启动组(24-48小时,40例)。治疗后48、72、96小时两组血钙均较治疗前升高,WBC、CRP、乳酸、IL-6、TNF-α、APACHE II和BISAP评分均较治疗前降低。晚期启动组治疗后72小时和96小时WBC、APACHE II、BISAP评分显著低于早期启动组(均P<0.05),胰腺脓肿发生率更低(5.00% vs 20.00%),但腹腔间隔室综合征发生率更高(42.50% vs 13.33%)。早期启动组ICU治疗时间更短(11.00天 vs 15.00天,P<0.05),两组住院费用、住院时间和病死率无统计学差异。

要点

  • 早期启动组(诊断至CBP<24小时)ICU治疗时间显著短于晚期启动组(24-48小时)[11.00(6.00,20.00)天 vs 15.00(9.75,25.00)天,P<0.05]。
  • 晚期启动组腹腔间隔室综合征发生率显著高于早期启动组[42.50%(17/40)vs 13.33%(12/90),P<0.05]。
  • 晚期启动组胰腺脓肿发生率显著低于早期启动组[5.00%(2/40)vs 20.00%(18/90),P<0.05]。
  • 治疗后72小时和96小时晚期启动组WBC、APACHE II、BISAP评分显著低于早期启动组(均P<0.05)。
  • 两组住院费用、住院时间和病死率无统计学差异。

适用人群与场景

  • 2020年1月至2023年12月在湖南省人民医院接受CBP治疗的SAP患者130例,其中早期启动组90例、晚期启动组40例。

诊断标准与关键阈值

  • 早期启动组:诊断SAP至首次CBP治疗时间<24小时;晚期启动组:诊断SAP至首次CBP治疗时间24-48小时。

研究设计与关键结果

  • 研究类型:回顾性队列研究;样本量130例(早期启动组90例,晚期启动组40例);人群:接受CBP治疗的SAP患者。
  • 治疗前两组性别、年龄、APACHE II评分、BISAP评分、病因及实验室检查指标无显著差异。
  • 治疗后48、72、96小时两组血钙水平均显著高于治疗前,WBC、CRP、乳酸、IL-6、TNF-α、APACHE II评分和BISAP评分均显著低于治疗前。
  • 治疗后72小时和96小时晚期启动组WBC、APACHE II评分、BISAP评分显著低于早期启动组(均P<0.05):WBC(×10⁹/L)72小时10.96(8.68,13.04)vs 12.45(8.93,16.30),96小时10.18(8.68,12.42)vs 11.96(8.81,16.87);APACHE II评分72小时9.50(5.75,12.00)vs 11.00(6.25,14.00),96小时10.00(4.00,12.00)vs 12.00(7.00,14.75);BISAP评分72小时2.35±1.03 vs 2.76±1.10,96小时2.08±1.21 vs 2.70±1.11。
  • 并发症:晚期启动组胰腺脓肿发生率显著低于早期启动组[5.00%(2/40)vs 20.00%(18/90)],腹腔间隔室综合征发生率显著高于早期启动组[42.50%(17/40)vs 13.33%(12/90)](均P<0.05)。
  • 早期启动组ICU治疗时间显著短于晚期启动组[11.00(6.00,20.00)天 vs 15.00(9.75,25.00)天,P<0.05];两组住院费用、住院时间和病死率无统计学差异。

证据类型、等级与局限

  • 证据类型:回顾性队列研究;局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,CBP可有效提高血钙水平、降低乳酸和炎症因子水平;诊断SAP后24-48小时内启动CBP可更快降低WBC水平和疾病严重程度评分,并减少胰腺脓肿的发生;诊断SAP后24小时内启动CBP可降低腹腔间隔室综合征发生率并缩短ICU治疗时间。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To observe the clinical effect of initiating continuous blood purification (CBP) treatment at different times for patients with severe acute pancreatitis (SAP), and to explore the optimal timing for starting CBP treatment for SAP, so as to provide evidence for clinicians to start CBP treatment.

METHODS: A retrospective cohort study was used to select patients with SAP who received CBP treatment in People's Hospital of Hunan Province from January 2020 to December 2023. According to the timing of CBP initiation, the patients were divided into early initiation group (diagnosis of SAP to the first CBP treatment time < 24 hours) and late initiation group (diagnosis of SAP to the first CBP treatment time of 24-48 hours). The general data, acute physiology and chronic health evaluation II (APACHE II), bedside index for severity in acute pancreatitis (BISAP) score and laboratory indicators, local complications and systemic complications, intensive care unit (ICU) treatment time, hospital stay, treatment cost, and clinical outcome of the two groups were collected and compared.

RESULTS: A total of 130 patients with SAP who received CBP treatment were enrolled, including 90 patients in the early initiation group and 40 patients in the late initiation group. Before treatment, there were no significant differences in gender, age, APACHE II score, BISAP score, etiology and laboratory examination indexes between the early initiation group and late initiation group. At 48, 72, 96 hours after treatment, the blood calcium level of the two groups was significantly higher than that before treatment, and the levels of white blood cell count (WBC), C-reactive protein (CRP), lactic acid, interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), APACHE II score and BISAP score were significantly lower than those before treatment. The WBC level, APACHE II score and BISAP score of the late initiation group were significantly lower than those of the early initiation group at 72 hours and 96 hours after treatment [WBC (×109/L): 10.96 (8.68, 13.04) vs. 12.45 (8.93, 16.30) at 72 hours after treatment, and 10.18 (8.68, 12.42) vs. 11.96 (8.81, 16.87) at 96 hours after treatment; APACHE II score: 9.50 (5.75, 12.00) vs. 11.00 (6.25, 14.00) at 72 hours after treatment, and 10.00 (4.00, 12.00) vs. 12.00 (7.00, 14.75) at 96 hours after treatment; BISAP score: 2.35±1.03 vs. 2.76±1.10 at 72 hours after treatment, and 2.08±1.21 vs. 2.70±1.11 at 96 hours after treatment], the differences were statistically significant (all P < 0.05). In terms of complications, the incidence of pancreatic abscess in the late initiation group was significantly lower than that in the early initiation group [5.00% (2/40) vs. 20.00% (18/90)], but the incidence of abdominal compartment syndrome was significantly higher than that in the early initiation group [42.50% (17/40) vs. 13.33% (12/90)], the differences were statistically significant (all P < 0.05). In addition, the ICU treatment time in the early initiation group was significantly shorter than that in the late initiation group [days: 11.00 (6.00, 20.00) vs. 15.00 (9.75, 25.00), P < 0.05], and there were no statistically significant differences in hospitalization costs, length of stay and mortality between the two groups.

CONCLUSIONS: CBP can effectively increase the level of blood calcium and decrease the level of lactic acid and inflammatory factors. Starting CBP within 24-48 hours after diagnosis of SAP can reduce WBC level and disease severity score faster, and reduce the occurrence of pancreatic abscess. Initiation of CBP within 24 hours after diagnosis of SAP can reduce the incidence of abdominal compartment syndrome and shorten the duration of ICU treatment.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Chen F, Xie R, Han X, et al. [Study on the clinical effect of initiating continuous blood purification at different times for severe acute pancreatitis]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2024. PMID: 39380514. doi:10.3760/cma.j.cn121430-20240408-00317

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。